Concurrent circulating tumor DNA and tissue-based testing identified more patients eligible for personalized cancer care than either of the tests done alone. There are two popular testing strategies ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal cancer (CRC) most likely to benefit from adjuvant therapy, analyses of two ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...

Researchers from various institutes, along with US biotech company Personalis, have found a test that can predict lung cancer outcomes by identifying circulating tumour DNA (ctDNA) in the blood.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a journal of the American Association ...

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...

Of the patients who were initially ctDNA positive and received pembrolizumab, 85% had ctDNA clearance at 6 months. Using circulating tumor DNA (ctDNA) test results to guide adjuvant treatment with ...

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that data utilizing its RaDaR ® 1.0 assay for the detection of ...

Despite the benefits of ctDNA testing in NSCLC, this is a relatively niche application. Whilst NSCLC makes up approximately 87% of lung cancers, only around 10-15% of NSCLC patients have cancer with ...

Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancer NeoGenomics will present new data from the SURVIVE HERoes ...